Secondary Intelligence™ Demo
Discover how Secondary Intelligence™ can support your compound assessments by predicting off-target activities and potential…
Certara2024年5月24日
Quantitative systems pharmacology-based exploration of relevant anti-amyloid therapy challenges in clinical practice
Addressing practical challenges in clinical practice after the recent approvals of amyloid antibodies in Alzheimer's…
Certara2024年5月22日
CERTAINTY Europe
GREATER CERTAINTY IN DRUG DEVELOPMENT Certainty by Certara offers exclusive access to Certara experts, industry leaders, and…
Danielle Pillsbury2024年5月22日
Clinical Pharmacology & Model-Informed Drug Development Insights for Targeted Radiation Therapies
標的放射線治療（TRT）は、腫瘍に対して選択的に細胞毒性のある放射線を届けます。In recent years, oncology drug…
Danielle Pillsbury2024年5月22日
Certara Appoints New Chief Human Resources Officer & General Counsel
RADNOR, PA – 2024年5月21日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in…
Danielle Pillsbury2024年5月21日
Accelerating the Progress of Kinase Inhibitors in Oncology
The potential of PBPK modeling in answering key questions around these drugs. Hannah Jones, PhDMasoud…
Certara2024年5月20日
Unlocking Efficiency in Formulation Development and Approvals with MIFD & Simcyp Biopharmaceutics [APAC Webinar]
Biopharmaceutical professionals can gain a significant edge in formulation development by attending this free webinar…
Danielle Pillsbury2024年5月16日
Reflections on the New FDA Clinical Pharmacology Guidance for Antibody-Drug Conjugates
In recent years, oncology drug developers have invested in antibody-drug conjugates (ADCs). These targeted therapies…
Certara2024年5月10日
CERTARA & CLOUDSCIENTIFIC ACCELERATE AI FOR DRUG DEVELOPMENT IN CHINA
Partnership will provide biopharmaceutical companies with advanced tools and solutions needed to expedite research …
Certara2024年5月10日
